These results strongly encourage more scientific research into ULK1 inhibitors in PDAC as they exert potent autophagic suppression and have shown synergistic anti-cancer activity with a variety of compounds such as upstream KRAS inhibitors (AMG510) [345], ERK inhibitors (SCH772984) [291], PARP inhibitors (for BRCA mutant tumors) [346] and gemcitabine [295,323,347]. The gene discussed is KRAS; the disease is cancer.